LGC

LGC provides customers across multiple markets with reference materials, proficiency testing, oligonucleotides, genomics reagents, and instrumentation.

The firms are also partnering to develop molecular diagnostic assays and for the supply of enzymes and oligonucleotides required for manufacturing.

The technology uses a proprietary chemistry that attaches primers to probes with a polyethylene glycol-based linker to prevent the formation of primer-dimers.

EASI-Genomics was launched earlier this year to provide free access to NGS technologies and genomic services to researchers from industry and academia.

LGC said the acquisition will improve its position across the clinical quality control tools market and increase its proficiency testing offerings.

CoPrimers use a proprietary chemistry that attaches primers to probes with a polyethylene glycol-based linker, which prevents the formation of primer-dimers.

LGC said that the acquisition will increase its presence in the nucleic acid market, in addition to its previous acquisitions in the last few years.

The deal marks the latest in a series of acquisition LGC has made in recent years to expand its presence on the nucleic acid chemistry market.

London-based LGC said that the acquisition increases its exposure to the next-generation sequencing and gene editing markets.